Roivant Sciences in exclusive joint venture talks with Arbutus; DBV gets green light to submit peanut allergy patch

→ Months after investing $116 million into Canada’s Arbutus $ABUS, Roivant Sciences confirmed early speculations that it’s exploring a joint venture deal. The companies spread word Wednesday that they have entered into a monthlong period of exclusive negotiations to jointly develop Arbutus’ nucleic acid delivery platform through a new company. Arbutus has built a rep for itself with both its in-house hepatitis B therapy and drugs from other companies, such as Alnylam’s patisiran, that utilize its delivery tech.

→ France’s DBV Technologies got a shot in the arm earlier this week when the FDA said it could submit its peanut allergy therapy for review. Investors cheered on the notion that the biotech’s disappointing data last fall didn’t doom its chances. There’s still a long road ahead on this one, though.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->